Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases

Abstract

This study suggests that imiquimod may be useful as a new therapy for the treatment of actinic keratoses.

TLR7 and TLR8 as targets in cancer therapy

“…In addition, several controlled clinical trials as well as many smaller series of cases and case reports have demonstrated that imiquimod is also effective against a variety of primary skin cancers as well as cutaneous metastases of some malignancies. Cutaneous tumors that have responded well to topical treatment with imiquimod include basal cell carcinomas (Sterry et al, 2002;BathHextall et al, 2004;Geisse et al, 2004;Gollnick et al, 2005;Schulze et al, 2005), keratoacanthomas (Dendorfer et al, 2003;Peris et al, 2003), actinic keratoses (Stockfleth et al, 2001(Stockfleth et al, , 2002Lebwohl et al, 2004;Szeimies et al, 2004;Korman et al, 2005) and Bowen's disease (the latter two entities represent epidermal carcinoma in situ) (Patel et al, 2006;Peris et al, 2006), cutaneous metastases of melanoma (Steinmann et al, 2000;Bong et al, 2002;Ugurel et al, 2002;Wolf et al, 2003;Zeitouni et al, 2005), some cases of primary melanoma in situ (Fleming et al, 2004;Kamin et al, 2005;Ray et al, 2005;Wolf et al, 2005;Lonsdale-Eccles et al, 2006) and cutaneous T-cell lymphomas (Suchin et al, 2002;Dummer et al, 2003b;Chong et al, 2004;Deeths et al, 2005). Clinical responses of cutaneous neoplasias to topical treatment with imiquimod have also been observed in difficult-to-treat patient populations, such as organ transplant patients under immunosuppressive therapy (Smith et al, 2001;Prinz et al, 2004;Brown et al, 2005) or Xeroderma pigmentosum patients suffering from rapid development of multiple UV-induced cutaneous malignancies …”

Facial Resurfacing for Nonmelanoma Skin Cancer Prophylaxis

“…7 More recently, the novel immunomodulator imiquimod has been reported to be effective in the treatment of AKs. 25 In a study by Stockfleth et al, 25 patients with a 5-to 16-year history of recurrent AKs were treated thrice weekly with 5% imiquimod cream for 6 to 8 weeks. All 6 patients were clinically and histologically completely cleared of AKs at the end of treatment.…”

Successful Treatment of Invasive Squamous Cell Carcinoma Using Topical Imiquimod

“…1,2 The recent success of topical immunomodulatory therapy with imiquimod for basal cell cancer, 3,4 actinic keratoses, 5 and intraepithelial carcinoma 6,7 prompted us to start the patient on a selfapplied regimen of 5% imiquimod cream to be applied 3 times per week and left on overnight for 8 hours.…”